These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 9230631

  • 1. A view on noradrenergic, hypothalamic-pituitary-adrenal axis and extrahypothalamic corticotrophin-releasing factor function in anxiety and affective disorders: the reduced growth hormone response to clonidine.
    Coplan JD, Pine DS, Papp LA, Gorman JM.
    Psychopharmacol Bull; 1997; 33(2):193-204. PubMed ID: 9230631
    [No Abstract] [Full Text] [Related]

  • 2. [The neuroendocrinology of stress and the pathophysiology and therapy of depression and anxiety].
    Ströhle A.
    Nervenarzt; 2003 Mar; 74(3):279-91; quiz 292. PubMed ID: 12627245
    [Abstract] [Full Text] [Related]

  • 3. Stress responsive neurohormones in depression and anxiety.
    Ströhle A, Holsboer F.
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S207-14. PubMed ID: 14677081
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Stimulation of the hypothalamic-pituitary-adrenal axis and inhibition of growth hormone release via increased central noradrenaline neuronal activity by urethane anaesthesia in the rat: blockade by clonidine.
    Smythe GA, Gleeson RM, Stead BH.
    Aust J Biol Sci; 1987 Nov; 40(1):91-6. PubMed ID: 3274655
    [Abstract] [Full Text] [Related]

  • 6. Do anxiety and depression have a common pathophysiological mechanism?
    Boyer P.
    Acta Psychiatr Scand Suppl; 2000 Nov; (406):24-9. PubMed ID: 11131467
    [Abstract] [Full Text] [Related]

  • 7. The role of the HPA axis in psychiatric disorders and CRF antagonists as potential treatments.
    Keller PA, McCluskey A, Morgan J, O'connor SM.
    Arch Pharm (Weinheim); 2006 Jul; 339(7):346-55. PubMed ID: 16783839
    [Abstract] [Full Text] [Related]

  • 8. The neurobiological basis of mixed depression-anxiety states.
    Gulley LR, Nemeroff CB.
    J Clin Psychiatry; 1993 Jan; 54 Suppl():16-9. PubMed ID: 8093884
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The hypothalamic-pituitary-adrenal axis during pregnancy.
    Blackburn S.
    J Perinat Neonatal Nurs; 2010 Jan; 24(1):10-1. PubMed ID: 20147825
    [No Abstract] [Full Text] [Related]

  • 11. Imidazoline2 (I2) receptor- and alpha2-adrenoceptor-mediated modulation of hypothalamic-pituitary-adrenal axis activity in control and acute restraint stressed rats.
    Finn DP, Hudson AL, Kinoshita H, Coventry TL, Jessop DS, Nutt DJ, Harbuz MS.
    J Psychopharmacol; 2004 Mar; 18(1):47-53. PubMed ID: 15107184
    [Abstract] [Full Text] [Related]

  • 12. Neuroendocrine measures in anorexia nervosa: comparisons with primary affective disorders.
    Müller EE, Cavagnini F, Panerai AE, Massironi R, Ferrari E, Brambilla F.
    Adv Biochem Psychopharmacol; 1987 Mar; 43():261-71. PubMed ID: 3035890
    [No Abstract] [Full Text] [Related]

  • 13. Longitudinal neuroendocrine changes assessed by dexamethasone/CRH and growth hormone releasing hormone tests in psychotic depression.
    Owashi T, Otsubo T, Oshima A, Nakagome K, Higuchi T, Kamijima K.
    Psychoneuroendocrinology; 2008 Feb; 33(2):152-61. PubMed ID: 18068306
    [Abstract] [Full Text] [Related]

  • 14. [Stress and central neuroendocrine networks].
    Morita K, Sekiyama A, Rokutan K.
    No To Shinkei; 2005 May; 57(5):397-406. PubMed ID: 15981639
    [No Abstract] [Full Text] [Related]

  • 15. The hypothalamic-pituitary-adrenal and the hypothalamic- pituitary-gonadal axes interplay.
    Mastorakos G, Pavlatou MG, Mizamtsidi M.
    Pediatr Endocrinol Rev; 2006 Jan; 3 Suppl 1():172-81. PubMed ID: 16641855
    [Abstract] [Full Text] [Related]

  • 16. Endocrine and behavioral effects of neuromedin S.
    Jászberényi M, Bagosi Z, Thurzó B, Földesi I, Telegdy G.
    Horm Behav; 2007 Dec; 52(5):631-9. PubMed ID: 17900576
    [Abstract] [Full Text] [Related]

  • 17. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyalgia.
    Torpy DJ, Papanicolaou DA, Lotsikas AJ, Wilder RL, Chrousos GP, Pillemer SR.
    Arthritis Rheum; 2000 Apr; 43(4):872-80. PubMed ID: 10765933
    [Abstract] [Full Text] [Related]

  • 18. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders.
    Ressler KJ, Nemeroff CB.
    Depress Anxiety; 2000 Apr; 12 Suppl 1():2-19. PubMed ID: 11098410
    [Abstract] [Full Text] [Related]

  • 19. Neuronal actions of glucocorticoids: focus on depression.
    Yu S, Holsboer F, Almeida OF.
    J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):300-9. PubMed ID: 17933520
    [Abstract] [Full Text] [Related]

  • 20. The corticotropin-releasing factor (CRF)(1) receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythms.
    Gannon RL, Millan MJ.
    Brain Res; 2006 Apr 14; 1083(1):96-102. PubMed ID: 16551464
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.